Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Cytiva-Cell & Gene Therapy WP 2
Stylus Medicine launches with $85m to advance in vivo gene editing
Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
MeiraGTx seeks UK approval after gene therapy restores sight in children born blind
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
GEMMABio raises $34m to advance gene therapy programmes
